MDT

The Week

Medtronic fell 3.41% this week to close at $90.96. The S&P 500 lost 0.8%, so the stock underperformed the benchmark by about 2.61 percentage points. The holiday-shortened week had just four sessions. Shares opened Tuesday at $93.25 but failed to hold gains, drifted lower on Wednesday, hit an intraday low of $90.58 on Thursday, and ended Friday near the low of the week. The weekly range was 3.36%, and average daily volume of 6.6m shares ran about 12.6% below the 60-day median.

Key Events

The week carried a fairly dense company news flow. Medtronic released its Q1 FY2027 earnings call transcript and stepped up its surgical robotics push. On 8 September, Orchestra BioMed highlighted over $500m in annual royalty potential from the AVIM pacemaker therapy partnered with Medtronic. On 9 September, Medtronic presented at the Wells Fargo conference, focusing on growth in AI, robotics and ablation. Earlier in the week the stock outperformed some peers on a down day, and some market commentary argued Wall Street is not paying enough attention to the high-yield healthcare name. On 11 September, analyst Brandon Vazquez reaffirmed a buy rating, citing a strong FY2027 outlook and an attractive risk-reward profile.

Analyst Ratings

A total of 30 institutions cover Medtronic. Of these, 20 rate it buy or overweight, 9 rate it hold, and 1 has no opinion; none rate it underweight or sell. The consensus rating is buy, with a consensus target price of $104.76, about 15.17% above the latest close of $90.96. Targets range from $85 to $121, showing meaningful dispersion. Medtronic ranks 4th by rating among 142 stocks in the medical device industry.

The Week Ahead

Next week’s macro calendar is heavy on US retail data. The New York Fed manufacturing index lands on 15 September, with a prior reading of 20.6 and a forecast of 14.75. On 16 September, retail sales, retail sales ex-autos, import prices, the NAHB housing market index and EIA crude inventories are all due. Retail sales have been choppy month to month. A soft print could weigh further on risk appetite for medical device names like Medtronic.

In Short

Medtronic shares moved lower this week even as the analyst backdrop leaned positive. The stock trades around 22.24x earnings with a dividend yield of 3.13%, mid-range for the medical device sector. On the latest trading day, large-lot money was a net buyer while small and medium orders tilted the other way, a split worth watching. Retail data next week will set the tone for broader risk appetite, while the surgical robotics and AI narrative still needs a clearer catalyst to narrow the gap between ratings and price action.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.